Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
Abstract Introduction Deucravacitinib, an oral tyrosine kinase 2 (TYK2) inhibitor, is approved in the United States to treat adults with moderate-to-severe plaque psoriasis (PsO). This study compared the long-term efficacy of deucravacitinib and adalimumab using results from long-term extension (LTE...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Adis, Springer Healthcare
2023-07-01
|
| Seri Bilgileri: | Dermatology and Therapy |
| Konular: | |
| Online Erişim: | https://doi.org/10.1007/s13555-023-00977-1 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|